GeneDx is trading 10.2% down at $87.90, underperforming the broader biotechnology sector, which is higher on September 22, 2026; no verified same-day company-specific catalyst was identified.
- Searches found no verified same-day announcement, earnings update, regulatory action, or other credible catalyst.
- The September 9 NPC GenomeComplete collaboration remains the latest confirmed company news.
- Previously reported short-seller allegations are not a new September 22 event.